Tamsulosin
From Wikipedia, the free encyclopedia
| Image:Tamsulosin.png | |
| Tamsulosin
| |
| Systematic (IUPAC) name | |
| (R)-5-(2-(2-(2-ethoxyphenoxy)ethylamino)propyl)- 2-methoxybenzenesulfonamide | |
| Identifiers | |
| CAS number | 106133-20-4 |
| ATC code | G04CA02 |
| PubChem | 129211 |
| DrugBank | APRD00036 |
| Chemical data | |
| Formula | C20H28N2O5S |
| Mol. weight | 408.51 |
| Pharmacokinetic data | |
| Bioavailability | 100% (oral) |
| Metabolism | hepatic |
| Half life | 9–13 hours |
| Excretion | 76% renal |
| Therapeutic considerations | |
| Pregnancy cat. |
B2 (Aust) |
| Legal status | |
| Routes | oral |
Tamsulosin (rINN) (IPA: [tæmˈsulosɪn, tæmsuˈlosɪn, ]) is an α1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH). Tamsulosin was developed by Yamanouchi Pharmaceuticals (now part of Astellas Pharma) and is marketed by various companies under licence, including Boehringer-Ingelheim and CSL. As of 2006, tamsulosin hydrochloride extended-release tablets are marketed under the trade name Flomaxtra. It was formerly marketed as modified-release capsules under the trade name Flomax.
Contents |
[edit] Clinical use
- Main article: Alpha blocker
[edit] Adverse effects
Two ADRs (Adverse Drug Reactions) have been reported:
- Immunologic: It contains a sulfa moiety, thus causing typical reactions to sulfa drugs.
- Ophtalmic: It causes complications during cataracts surgery.
[edit] Clinical comparison
Although prostate specific, it does not have the prostate apoptotic effects of other alpha-blockers such as doxazosin and terazosin.
[edit] External links
- Tamsulosin (systemic) – information from USP DI Advice for the Patient
- Flomax (drugs.com) – U.S. product information
- Flomax (Official Site) – Official Site
